Fireweed Metals Corp. awarded up to C$35.4 M in joint US-Canadian government funding to advance Mactung and essential Infrastructure to unlock the critical minerals district at Macmillan Pass, Yukon Territoryanjili tree in kerala 。

Giants release quarterback Daniel Jones just days after benching him EAST RUTHERFORD, N.J. (AP) — The Daniel Jones era in New York is over. The Giants quarterback was granted his release by the team just days after the franchise said it was benching him in favor of third-stringer Tommy DeVito. New York president John Mara said Jones approached the team about releasing him and the club obliged. Mara added he was “disappointed” at the quick dissolution of a once-promising relationship between Jones and the team. Giants coach Brian Daboll benched Jones in favor of DeVito following a loss to the Panthers in Germany that dropped New York's record to 2-8. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

New Delhi [India], November 30 (ANI): The Indian sports industry is likely to reach USD 100 billion by 2027, from USD 27 billion in 2020, according to a report by FICCI-Nangia Nxt. FICCI-Nangia Nxt Knowledge Report – ‘Future of Sports in India’, which was released on Saturday, added that the Indian sports industry is experiencing a period of dynamic growth. This transformation is driven by various factors, including the commercialization of sports leagues, technological advancements, and a growing emphasis on diverse sporting disciplines, the report said. Sectors such as sports goods, apparel, and media rights are contributing significantly to this growth, with the sports media market alone expected to grow from USD 1 billion in 2020 to USD 13.4 billion by 2027, as per the report. It further added that the landmark achievements by Indian athletes at the 2023 Asian Games and the 2024 Paris Olympics have highlight the nation’s increasing competitiveness on the global stage. The sports goods market alone, valued at USD 4.5 billion in 2020, is expected to reach USD 6.6 billion by 2027, while the sports apparel sector is projected to grow from USD 14 billion in 2020 to USD 21 billion by 2023, driven primarily by men’s sportswear products, as per the report. The growth in sports-related businesses extends to sponsorships, media rights, and merchandising, further strengthening the sector’s overall ecosystem. Kunal, Joint Secretary, Ministry of Youth Affairs and Sports on Saturday emphasized the importance of sports and said that sports play an important role in shaping the economy. “The government needs to ensure that the governance of sports is proper, just and equitable so that those who want to play should get the opportunity along with developing the entire eco-system,” he added while addressing the 14th Global Sports Summit, ‘FICCI TURF 2024’. Kunal further stated that India has announced to host the Olympics in 2036 and there is a need for all stakeholders to work together to not only achieve the target of 2036 but also of vision of India at 2047. He added the two documents – Sports Policy 2024 and draft National Sports Governance Bill, are currently in the public domain for further consultation. “Very soon we are going to give the final shape to both these two documents. These documents are required as sports is not about sports, but it is the driver of the economy,” he emphasized. Manika Batra, Olympian and Indian Table Tennis Player said, “I have seen changes occurring in the sports sector and I am thankful for the support we are now getting from the government and particularly the Sports Ministry. Further, the support from the corporate sector will be beneficial for the sector and players.” (ANI) This report is auto-generated from ANI news service. ThePrint holds no responsibility for its content. var ytflag = 0;var myListener = function() {document.removeEventListener('mousemove', myListener, false);lazyloadmyframes();};document.addEventListener('mousemove', myListener, false);window.addEventListener('scroll', function() {if (ytflag == 0) {lazyloadmyframes();ytflag = 1;}});function lazyloadmyframes() {var ytv = document.getElementsByClassName("klazyiframe");for (var i = 0; i < ytv.length; i++) {ytv[i].src = ytv[i].getAttribute('data-src');}} Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );ATLANTA (AP) — Georgia Senate Republicans recommended on Friday that the state write laws banning transgender girls and women from participating in high school and college sports, setting the stage for action in the 2025 legislative session. The vote by a committee that was studying the issue is hardly a surprise. Lt. Gov. Burt Jones — a possible Republican contender for governor in 2026 — announced almost identical goals at the panel's first meeting in August . It’s an issue that’s already been addressed in Georgia. Legislators in 2022 empowered the Georgia High School Association to regulate transgender students' participation in sports. The association, which regulates sports and activities for all public schools and some private schools, then banned transgender boys and girls from playing on the school sports teams matching their gender identity. Jones and others argue that doesn't go far enough and that lawmakers themselves need to act. It's a sign Republicans believe there is more political gain in fears about transgender women playing women’s sports or using women’s bathrooms. At least 26 mostly Republican states have passed laws or rules to restrict transgender girls from participating high school sports and, in some cases, transgender women from college sports , according to the Movement Advancement Project, a gay rights group. In Georgia, additional action appears more likely now after House Speaker Jon Burns and Gov. Brian Kemp, both Republicans, have voiced support for further legislation. Jeff Graham, executive director of the LGBTQ+ advocacy group Georgia Equality, said his group is playing defense, concerned about the possibility of other bills that could further restrict gender-affirming care or ban transgender people from using public bathrooms that match their gender identity. “We’re expecting that it’ll be at least what we saw in 2023 and 2024, with the number of bills and more than likely laws,” Graham told reporters Friday. But Burns, from Newington, has said he's not interested in other bills dealing with transgender people besides those dealing with girls' and women's sports. Republican State Sen. Greg Dolezal, of Cumming, who led the Senate study committee, said Friday that he, too, is not interested in a broader bill regulating bathroom usage, although his committee recommended that schools that host sporting events require athletes to use locker rooms based on their assigned sex at birth. Dolezal said senators would seek to write legislation that regulated public schools and colleges, as well as private institutions that compete against public schools and colleges. The committee also recommends that people be able to sue or file grievances if schools break the rules, and that state money be withheld from schools that break the rules. Supporters of more action have focused on the 2022 NCAA women’s swimming championships at Georgia Tech in Atlanta, where Lia Thomas, a transgender woman, swam for the University of Pennsylvania and won the 500-meter freestyle . The NCAA has since revised its policy on transgender women’s participation, saying it will follow the rules of respective athletics federations. World Aquatics, the swimming governing body, banned transgender women who have been through male puberty from competing in women’s races. That means Thomas wouldn’t be allowed to swim in NCAA events today. “My basic contention that this is a solution in search of a problem remains,” Graham said. He said he fears that many people who oppose laws that seek to restrict transgender people will be afraid to testify and lobby at the Georgia Capitol, citing assault charges against a man accused of shaking U.S. Rep. Nancy Mace in a Capitol office building in Washington, D.C. Dolezal repeatedly tried to turn down the emotional temperature of the issue on Friday. “I think that there’s a group of people that wants to be respected and I think that they deserve respect,” Dolezal told reporters. “But I also think that you can be respectful, but also recognize that in the sporting arena, fairness and competition is important.”DALLAS (AP) — The championship vision that led Nathan Eovaldi to sign with Texas as a free agent two years ago is the same one that brought him back to the Rangers. A World Series title in his first season was followed by a losing record this year. “I believe in the guys in the group that we have. We were able to do it in ‘23. I don’t feel a lot has changed,” Eovaldi said Friday, a day after finalizing a $75 million, three-year contract . “We had a down year last year, but I've said it before, you learn a lot from losing seasons.” Eovaldi had declined a $20 million player option to become a free agent again and reached an agreement during the winter meetings in Dallas. Texas also acquired slugging corner infielder Jake Burger in a swap with Miami. Burger had fallen asleep before getting a call late Tuesday night that he had been traded to Texas, where his family is planning to move after the October birth of a daughter with Down syndrome. “The other city that is really good other than Nashville in terms of children's hospital and resources for her Downs is in Dallas," Burger said. “Not just from the baseball spectrum, from the life aspect as well ... I feel like it was meant to be, and we couldn’t be more more excited about that.” In the Nashville area, Burger lives close to Rangers manager Bruce Bochy, whom he plans to visit with soon. His former Marlins manager, Skip Schumaker , was hired last month by the Rangers as a senior adviser for baseball operations, and Luis Urueta, Miami’s bench coach the past two seasons, recently joined Bochy’s on-field coaching staff for 2025. Burger and Rangers pitcher Dane Dunning were once roommates in the Chicago White Sox organization. Burger hit .250 with 29 home runs and 76 RBIs in 137 games for the Marlins last season, when he started 59 games at third base and 50 starts at first. He was with the White Sox in Texas when he got traded to Miami on Aug. 1, 2023, and four days later hit his first homer with the Marlins at Globe Life Field. Story continues below video When the Rangers made the title run in 2023, Eovaldi was 5-0 with a 2.95 ERA in six postseason starts. He was the winning pitcher in their World Series-clinching Game 5 at Arizona. He was also part of Boston’s 2018 title. Eovaldi was 12-8 this year with a 3.80 ERA in 29 starts, the last seven scoreless innings in the regular-season finale. He is 24-13 with a 3.72 ERA in 54 starts for Texas the past two seasons. The new deal for the Texas native, who who turns 35 in February, includes a $12 million signing bonus, half payable on Nov. 15, 2026, and the rest on Jan. 15, 2028, and salaries of $18 million next season, $25 million in 2026 and $20 million in 2027. He gets a full no-trade provision. After being welcomed back by Chris Young, the team's president of baseball operations, the pitcher said he never felt like he really left. The Rangers stayed in contact throughout the process after he declined his option Nov. 4. “Kind of listening to the market and everything, I’m extremely happy to be back. I’m glad we were we were able to make it all work out,” Eovaldi said. “We had a lot of teams reach out right away and we were in contact with most them across the league. Ultimately we were able to make it back here.” AP MLB: https://apnews.com/hub/mlb

National Perspective: Trump’s planned ‘great upheavel’ has a dismal precedent( MENAFN - media OutReach Newswire) SUNNYVALE, USA & HONG KONG SAR - Media OutReach Newswire - 3 December 2024 - AlikeAudience, a company directly integrated with major demand side platforms and data marketplaces worldwide that provides premium omnichannel audience data to brands, has announced its victory in three categories at this year's Marketech APAC Marketing technology Awards. The gala awards night, held in Singapore on November 28, awarded AlikeAudience for Best Customer Data Platform, Best AI Marketing Solution, and Best Mobile Marketing Solution. "The AlikeAudience team is proud to be recognized by the Marketech APAC team, and the top panel of industry judges," said AlikeAudience Managing Director Jeremy Lo. "We believe the AdTech industry, particularly in the key area of data utilization, will increasingly rely on AI-powered, privacy-compliant solutions. AlikeAudience is at the forefront of this advancement, providing platform and tech-agnostic solutions to meet industry needs." AlikeAudience offers bespoke demographic, interest, and app data, and has more than seven thousand audience segments in the US and APAC across the key sectors of FMCG, automotive, e-commerce, entertainment, travel, and hospitality. The company assembles its audience data from a combination of location signals, app data, and demographic data and connects these data points with insights from market research to generate methodologies to deliver targetable segments for media activation. Lo also said marketers in Asia must adapt their strategies for first, second, and third party data to effectively navigate diverse market dynamics and regulations. "An innovative approach is essential to take advantage of technological advances," Lo said. "With strong US coverage, AlikeAudience can apply global insights while localizing strategies to meet APAC advertisers' data needs, helping future-proof their business." AlikeAudience was founded in Sunnyvale, California, in 2015, and operates in the US, Asia, and Australia. MENAFN02122024003551001712ID1108949084 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

President-elect John Dramani Mahama expressed profound gratitude to God for his victory in the 2024 presidential election, acknowledging the divine guidance he believes has been central to his journey. In his first address to the nation following the official declaration of the results, Mahama described how God has proven Himself mightily in his life, a sentiment he could not disprove. “I thank God for preparing a table before me in the presence of my enemies. We are all acquainted with this Bible verse, anointing my head with oil and making my cup runneth over,” Mahama said, while expressing heartfelt thanks to his family. He particularly acknowledged his wife, Lordina Mahama, and their children for their unwavering support during challenging times. “I give thanks to my family, my children, my siblings, and all my extended family for standing by me through all these difficult times when victory and success seemed out of sight.” The President-elect also paid tribute to his Vice President-elect, Professor Jane Naana Opoku-Agyemang, for her groundbreaking role in Ghana’s political history as the first female vice president. Mahama commended her for her decency, humility, and sense of responsibility, noting that her leadership has opened doors for women across the country. “Naana, your decency, your humility, and your sense of responsibility are overwhelming. You’ve not only opened the door but continue to keep it open for other women,” Mahama said. He further added that Opoku-Agyemang’s victory symbolizes a new era, celebrating the fact that Ghana has made history by electing its first female vice president. Mahama also confirmed that he will meet with outgoing President Nana Addo Dankwa Akufo-Addo on December 11, 2024, at the Jubilee House to discuss the transition process and ensure a smooth handover of power.Donald Trump hinted he still wants to buy Greenland, a self-ruling territory of Denmark, saying that U.S. ownership and control of the island is an “absolute necessity” for national security. The U.S. President-elect reopened a debate from 2019, when he offered to buy what is the world’s biggest island, a proposal that was quickly rebuffed by Denmark at the time. “For purposes of National Security and Freedom throughout the World,” Trump said on Truth Social Sunday, “the United States of America feels that the ownership and control of Greenland is an absolute necessity.” Greenland is already crucial to American national defense, being home to a U.S. air base and a radar station. The war in Ukraine has dramatically increased the territory’s military value to the U.S. and NATO, given the island’s strategic location between the Arctic and the North Atlantic. Trump made the statement on Sunday as he nominated PayPal co-founder Ken Howery for U.S. ambassador to the Kingdom of Denmark. Howery responded on X saying he would work to “deepen the bonds” between the U.S., Denmark and Greenland. Howery was an ambassador to Sweden from 2019 to 2021, under Trump’s first administration. Commenting on Trump’s post, Greenland’s Prime Minister Mute Bourup Egede said by email that the island is “not for sale and will never be for sale.” However, he said Greenland must continue to be open to cooperation and trade directly with other countries, especially its neighbors. The autonomous authority published a blueprint for its foreign, security and defense policy earlier this year, in which it outlined hopes to forge closer links with North America through trade in critical minerals and by having a bigger say in key defense relationships that have historically been governed by Denmark. Trump’s proposal to buy Greenland in 2019 triggered tensions between the U.S. and Denmark, with Prime Minister Mette Frederiksen describing it as “absurd,” making it clear Greenland was not for sale. — Bloomberg NewsNon-Cystic Fibrosis Bronchiectasis Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies Involved by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici 12-23-2024 11:12 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2024 [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market. Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report: * Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years. * Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment * Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years. * In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology company dedicated to developing high-purity, pathogen-specific bacteriophage therapeutics for chronic pulmonary diseases and antibiotic-resistant bacterial infections, today announced promising topline results from its Phase 2 "Tailwind" trial. The trial evaluated AP-PA02, a novel inhaled multi-phage therapeutic for treating chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections in patients with non-cystic fibrosis bronchiectasis (NCFB). * In May 2024, Insmed's stock more than doubled following the announcement that its lead pipeline candidate, brensocatib, successfully completed a Phase III trial. The much-anticipated ASPEN trial (NCT04594369) was a global, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. * In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY. Non-Cystic Fibrosis Bronchiectasis Overview Non-cystic fibrosis bronchiectasis is a chronic lung condition characterized by the permanent widening and damage of the airways in the lungs, which leads to persistent coughing, excessive mucus production, and frequent respiratory infections. Unlike cystic fibrosis, it is not caused by a genetic defect in the CFTR gene. Non-cystic fibrosis bronchiectasis can result from various underlying conditions such as chronic infections, immune system disorders, or other lung diseases. Symptoms include chronic cough, shortness of breath, and fatigue. Treatment typically involves antibiotics to manage infections, bronchodilators, and airway clearance techniques to reduce symptoms and improve lung function. Get a Free Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight [ https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include: * NP339: NovaBiotics Ltd * Research Programme:NCFB: Synspira Therapeutics * Research programme: mucolytic agents: Parion Sciences * CHF 6333: Chiesi Farmaceutic * CSL787: CSL Behring * HSK31858: Haisco Pharmaceutical * S-1226: SolAeroMed Inc. * Benralizumab: AstraZeneca * Colistimethate sodium: Zambon SpA * BI 1291583: Boehringer Ingelheim * AP-PA02: Armata Pharmaceuticals * ARINA-1: Renovion Non-Cystic Fibrosis Bronchiectasis Route of Administration Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as * Intravenous * Subcutaneous * Oral * Intramuscular Non-Cystic Fibrosis Bronchiectasis Molecule Type Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as * Monoclonal antibody * Small molecule * Peptide Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment * Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type * Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type * Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration * Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration * Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type * Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type DelveInsight's Non-Cystic Fibrosis Bronchiectasis Report covers around 15+ products under different phases of clinical development like * Late-stage products (Phase III) * Mid-stage products (Phase II) * Early-stage product (Phase I) * Pre-clinical and Discovery stage candidates * Discontinued & Inactive candidates * Route of Administration Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include: Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are - Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others. Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis: The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment. * Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers * Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market. Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers * However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth. Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight * Coverage: Global * Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others * Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others * Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies * Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Table of Contents 1. Non-Cystic Fibrosis Bronchiectasis Report Introduction 2. Non-Cystic Fibrosis Bronchiectasis Executive Summary 3. Non-Cystic Fibrosis Bronchiectasis Overview 4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment 5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics 6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III) 7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II) 8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I) 9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products 10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment 11. Non-Cystic Fibrosis Bronchiectasis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Non-Cystic Fibrosis Bronchiectasis Key Companies 14. Non-Cystic Fibrosis Bronchiectasis Key Products 15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs 16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers 17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion 18. Non-Cystic Fibrosis Bronchiectasis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=noncystic-fibrosis-bronchiectasis-pipeline-insights-2024-therapies-clinical-trials-and-key-companies-involved-by-delveinsight-insmed-inc-astrazeneca-zambon-csl-behring-chiesi-farmaceutici ] Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.Cyclone Fengal: TN health department to conduct 500 medical camps in red alert districts on December 1

Zaire Williams, Zavier Fitch combine for 45 points to help Wagner beat Penn State-Scranton 120-30WVU routs Boise State to move to 8-0, eyes Showcase titleThe judge said he’ll make his decision after Combs’ lawyers and federal prosecutors file letters, due Monday, addressing outstanding issues.

RBA board reform: Special attention for interest rates or political bin fire?Patrick Mahomes was pumped up when the NFL schedule was released and he saw his Kansas City Chiefs were playing on Christmas Day for the second straight season. His excitement lasted for only a short time. "Until I realized it was on Wednesday," Mahomes said Monday. Plenty of sore bodies will take the field Wednesday when the Chiefs (14-1) visit the Pittsburgh Steelers (10-5) in what will be the third game in 11 days for both teams. Both squads just played on Saturday. The Chiefs posted a 27-19 home win over the Houston Texans and the Steelers fell 34-17 to the host Baltimore Ravens. "You're not going to feel great," Mahomes said of the short week. "That's kind of just what it is. You don't make excuses in this league. You go out and play football, and you fight until the very end, and you try to get a win at the end of the day. "You're motivated to play a great football team, to play in Pittsburgh in a great environment, a great stadium. It'll be rocking playing on Christmas, so everybody's going to be watching." If Kansas City wins Wednesday, it clinches the No. 1 seed and home-field advantage throughout the AFC playoffs. The Chiefs have 14 victories for the third time in the past five seasons. The franchise has never won 15 games in a season. Kansas City hasn't committed a single turnover during its five-game winning streak. Steelers quarterback Russell Wilson isn't fond of hearing "turnover" after he made two big mistakes in Saturday's loss to the Ravens. Wilson lost a fumble after a 19-yard gain to the Baltimore 4-yard line in the second quarter and later was intercepted by Marlon Humphrey, who returned it 37 yards for a touchdown early in the fourth quarter. Wilson called it "unacceptable" and now has his focus on making amends against Kansas City. "I don't think there's enough time to really sulk or worry or fear," Wilson said. " ... The one thing I'm not going to do is keep my head down, though. I know for us we got so much great confidence in who we are and what we can do and how we're going to respond. "We can't let a tough game like this take us into a negative state of mind because there's a lot more to play for and a lot more we're searching for, and we can still win the (AFC) North." Wilson is correct. If the Steelers win their final two regular-season games, they will win their division. They would have clinched it last weekend if they had won in Baltimore. Pittsburgh coach Mike Tomlin is hardly concerned about Wilson's miscues. It was the veteran signal-caller's first time committing multiple turnovers in nine games with the team. "He's tough on himself because he's got a desire to be great," Tomlin said. "He wants to lead us to victory. He owns that. I don't expect that to be an issue in terms of his readiness or trajectory of this week." Cornerback Joey Porter Jr. (knee) and receiver Ben Skowronek (hip) missed Pittsburgh's walkthrough on Monday. Standout receiver George Pickens (hamstring) was a full participant and may return after missing the past three games. Safety DeShon Elliott (hamstring), cornerback Donte Jackson (back) and defensive tackle Larry Ogunjobi (groin) also could return to action. Jackson's return would be big if Porter can't play. Kansas City also held a walkthrough on Monday. Left tackle D.J. Humphries (hamstring), safety Chamarri Conner (concussion) and star defensive end Chris Jones (calf) missed the session. Jones was injured against Houston. Meanwhile, Mahomes said his sore ankle is feeling better than it did last week. The Chiefs lost 20-14 to the visiting Las Vegas Raiders on Christmas Day last season. Kansas City has won the past three meetings with the Steelers, including a 42-21 rout in an AFC wild-card game on Jan. 16, 2022. --Field Level Media

How missing teen Maia Johnston's Upper Hutt rescue unfolded

Strictly mystery as Nadiya and former partner Dan Walker celebrate her birthday together – but keep cosy meal a secretFamed Colombian drug lord Fabio Ochoa released from US prison and deportedUs Weekly has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! This cold snap has us ready to hibernate indoors! If you’re as eager as Us to spend winter days at home, stocked with movies, snacks and your softest loungewear, it’s worth making your self-care routine as stylish as possible. Now is the perfect time to treat yourself to satiny pajamas, like the cozy-chic Gigi Bow pajama set from Mestiza New York. This pretty pick will have you looking as good as you feel and the sweet blue colorway is the epitome of style. Slip out of a hot bath and into comfort while simultaneously bringing glamour back to home dressing. This pajama set — which is available in sizes XS-XL — also happens to make a lovely gift! While no doubt luxe, Mestiza New York’s limited-edition, hand-painted bow pajamas are thankfully low maintenance. Made from a breathable, silky fabric that’s machine washable, wrinkle-free and has a touch of stretch, you’ll be reaching for your new favorite pair all year long. The bottoms feature an elastic waistband for comfort and even have practical pockets! These pajamas are also made to last. Mestiza is a mission-driven fashion company looking to reduce disposable clothes that end up in our landfills. Instead, the woman-founded company makes high-quality classic dresses and loungewear that stay beautiful for years, and to ensure top quality and prevent waste, the brand makes small quantities of each piece. Mestiza brings the same sophisticated designs as the brand’s evening and resort collections to its loungewear, so you won’t want to hide this set under a robe. The label offers striking designs for day and night. Mestiza New York is a woman-owned company and the founder, Louisa Rechter, is a Tory Burch Foundation Fellow. The Tory Burch Foundation supports women entrepreneurs by providing access to capital, education and community. Check our latest news in Google News Check our latest news in Apple News

The S&P 500 ended 0.7% higher after having been down 0.5% in the early going. The Dow Jones Industrial Average also recovered from an early slide to eke out a 0.2% gain. The tech-heavy Nasdaq composite rose 1%. Gains in technology and communications stocks accounted for much of the gains, outweighing losses in consumer goods companies and elsewhere in the market. Semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, rose 3.7%. Broadcom climbed 5.5% to also help support the broader market. Walmart fell 2% and PepsiCo slid 1%. Japanese automakers Honda and Nissan said they are talking about combining in a deal that might also include Mitsubishi Motors. U.S.-listed shares in Honda jumped 12.7%, while Nissan ended flat. Eli Lilly rose 3.7% after announcing that regulators approved Zepbound as the first and only prescription medicine for adults with sleep apnea. Department store Nordstrom fell 1.5% after it agreed to be taken private by Nordstrom family members and a Mexican retail group in a $6.25 billion deal. All told, the S&P 500 rose 43.22 points to 5,974.07. The Dow gained 66.69 points to 42,906.95. The Nasdaq rose 192.29 points to 19,764.89. Traders got a look at new snapshot of U.S. consumer confidence Monday. The Conference Board said that consumer confidence slipped in December. Its consumer confidence index fell back to 104.7 from 112.8 in November. Wall Street was expecting a reading of 113.8. The unexpectedly weak consumer confidence update follows several generally strong economic reports last week. One report showed the overall economy grew at a 3.1% annualized rate during the summer, faster than earlier thought. The latest report on unemployment benefit applications showed that the job market remains solid. A report on Friday said a measure of inflation the Federal Reserve likes to use was slightly lower last month than economists expected. Worries about inflation edging higher again had been weighing on Wall Street and the Fed. The central bank just delivered its third cut to interest rates this year, but inflation has been hovering stubbornly above its target of 2%. It has signaled that it could deliver fewer cuts to interest rates next year than it earlier anticipated because of concerns over inflation. Expectations for more interest rate cuts have helped drive a roughly 25% gain for the S&P 500 in 2024. That drive included 57 all-time highs this year. Inflation concerns have added to uncertainties heading into 2025, which include the labor market's path ahead and shifting economic policies under an incoming President Donald Trump. "Put simply, much of the strong market performance prior to last week was driven by expectations that a best-case scenario was the base case for 2025," said Brent Schutte, chief investment officer at Northwestern Mutual Wealth Management Company Treasury yields rose in the bond market. The yield on the 10-year Treasury rose to 4.59% from 4.53% late Friday. European markets closed mostly lower, while markets in Asia gained ground. Wall Street has several other economic reports to look forward to this week. On Tuesday, the U.S. will release its November report for sales of newly constructed homes. A weekly update on unemployment benefits is expected on Thursday. Markets in the U.S. will close at 1 p.m. Eastern on Tuesday for Christmas Eve and will remain closed on Wednesday for Christmas.Stock market today: Wall Street rises at the start of a holiday-shortened weekHow to buy Florida Gators vs. Tulane Green Wave Gasparilla Bowl ticketsFlorida Lawmaker Switches to Republican Party After Winning Election as a Democrat: 'I'm Tired of Being the Party of Protesting'

UConn head coach Dan Hurley insists he's not overvaluing Wednesday night's game between his 25th-ranked Huskies and No. 15 Baylor in Storrs, Conn. Sure, it comes on the heels of the two-time reigning national champion Huskies (5-3) responding to losing all three games during the Maui Invitational with a blowout victory over Maryland Eastern Shore on Saturday. UConn, which had won 17 consecutive games entering the Maui tournament, fell 23 spots from No. 2 to nearly out of the Associated Press Top 25 poll released Monday. "I think it's such a long season and we're eight games in," Hurley said when asked about facing the Bears. "Our performance in Maui shocked the college basketball world and the sports world, and obviously a lot went on there." "I don't think it's a must-win game in Game Nine of the season, but it's an opportunity to play in Gampel (Pavilion), where we play great and are very comfortable, and we know we're gonna have a great crowd." "We also know we're playing a top-level team, so it's a big game for us and it's a big game for them." Wednesday's game signifies the start of a tough stretch in UConn's schedule. The Huskies will visit Texas on Sunday and challenge No. 7 Gonzaga in New York on Dec. 14 before beginning Big East play on Dec. 18 against Xavier, which fell from No. 22 to out of the poll on Monday. But let's go back to Saturday's 99-45 dismantling of the Hawks. Jaylin Stewart started in place of the injured Alex Karaban (head) and joined Liam McNeeley by scoring 16 points to put UConn back in the win column. Solo Ball contributed 12 points, Aidan Mahaney had 11 and Tarris Reed Jr. (10 points, 12 rebounds) and Jayden Ross (10 points, 10 rebounds) each recorded a double-double. "This experience they're getting, (Stewart), Jayden Ross, Solo Ball, these guys are going to keep getting better and better," Hurley said. "Jaylin Stewart has flashed. That Memphis game (in which he scored 16 points on 7-of-9 shooting), he flashed a lot in that one. "... These sophomores are just going to keep getting better and better. That's why I do think we do need the grace and support of our people here at UConn. Because they're going to be such different players in January and February." Coming off a split in the Bahamas, Baylor (5-2) bounced back from a 77-62 setback to then-No. 11 Tennessee on Nov. 22 with a decisive 91-60 victory over New Orleans last Wednesday. "I know we're all a little tired," Bears coach Scott Drew said. "Whenever you come back from the Bahamas and a trip like that, the first game, you can be playing in mud. And I think the guys did a pretty good job, for the most part." Jayden Nunn drained six of his seven 3-pointers in the first half and finished with a season-high 23 points to power Baylor past the Privateers. Robert Wright III scored 18 points, Jeremy Roach had 17 and Miami transfer Norchad Omier recorded his third consecutive double-double after finishing with 12 points and a season-high 13 rebounds. --Field Level MediaDutch investor Prosus to raise bets on India

Hitster, the perfect party game, is now available in PHLOne of Colombia ’s legendary drug lords and a key operator of the Medellin cartel has been deported back to the South American country, after serving 25 years of a 30-year prison sentence in the United States. A short while later, Fabio Ochoa was again a free man. > Philadelphia news 24/7: Watch NBC10 free wherever you are Ochoa arrived in Bogota on a deportation flight on Monday afternoon, wearing a modest grey sweatshirt and carrying his personal belongings in a plastic bag. After stepping out of the plane, Ochoa was met by immigration officials in bullet proof vests. There were no police on site to detain him. Immigration officials took his fingerprints and confirmed through a database that Ochoa is not wanted by Colombian authorities. The country's immigration agency said on the social media platform X that Ochoa was “freed so that he could join his family.” “I was framed,” Ochoa claimed as reporters at Bogota’s El Dorado Airport asked if he regretted his actions. The former cartel boss smiled as he hugged his daughter, whom he had not seen in seven years, and said he would go to Medellin to live with his family. “The nightmare is over” said Ochoa, 67. Stories that affect your life across the U.S. and around the world. Ochoa and his older brothers amassed a fortune when cocaine started flooding the U.S. in the late 1970s and early 1980s, according to U.S. authorities, to the point that in 1987 they were included in the Forbes Magazine’s list of billionaires. Living in Miami, Ochoa ran a distribution center for the cocaine cartel once headed by Pablo Escobar. Escobar died in a shootout with authorities in Medellin in 1993. Ochoa was first indicted in the U.S. for his alleged role in the 1986 killing of Barry Seal, an American pilot who flew cocaine flights for the Medellin cartel, but became an informant for the Drug Enforcement Administration. Along with his two older brothers, Juan David and Jorge Luis, Ochoa turned himself in to Colombian authorities in the early 1990s under a deal in which they avoided being extradited to the U.S. The three brothers were released from prison in 1996, but Ochoa was arrested again three years later for drug trafficking and was extradited to the U.S. in 2001 in response to an indictment in Miami naming him and more than 40 people as part of a drug smuggling conspiracy. He was the only suspect in that group who opted to go to trial, resulting in his conviction and a 30-year sentence. The other defendants got much lighter prison terms because most of them cooperated with the government. Ochoa’s name has faded from popular memory as Mexican drug traffickers take center stage in the global drug trade. But the former member of the Medellin cartel was recently depicted in the Netflix series "Griselda," where he first fights the plucky businesswoman Griselda Blanco for control of Miami's cocaine market, and then makes an alliance with the drug trafficker, played by Sofia Vergara. Ochoa is also depicted in the Netflix series "Narcos," as the youngest son of an elite Medellin family that is into ranching and horse breeding and cuts a sharp contrast with Escobar, who came from more humble roots. Richard Gregorie, a retired assistant U.S. attorney who was on the prosecution team that convicted Ochoa, said authorities were never able to seize all of the Ochoa family’s illicit drug proceeds and he expects that the former mafia boss will have a welcome return home. “He won’t be retiring a poor man, that’s for sure,” Gregorie told The Associated Press earlier this month.

Finish strong? Rutgers did more than that in rout of Michigan State | ObservationsGeorgia Republicans recommend further law to restrict transgender women's participation in sports